This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Live Chat: 2012 Preview

BOSTON ( TheStreet) -- Welcome to December's Biotech Stock Mailbag Live Chat. The floor is yours.

I'm here for the next 90 minutes to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing.

Is there any hope for BioSante Pharma's (BPAX) future after the Libigel blow up? What about Antares Pharma (AIS) -- is it also mortally wounded?

Vertex Pharmaceuticals (VRTX) announced a CEO swap this morning Surprised? Does this signal more changes in store for the company as it transitions from a focus on hepatitis C to cystic fibrosis?

We can talk about YM BioSciences (YMI) and what lies ahead after this week's presentation of strong data on the myelofibrosis drug CYT387. Can YM Bio's market cap catch up to that of rival Incyte (INCY)?

Were you confused by this week's Alexza Pharmaceuticals (ALXA - Get Report) FDA panel? Me too, but let's hash out the future for Adasuve.

The year is almost over, so it's time to look ahead to key biotech events in 2012, including results from late-stage cancer immunotherapy trials involving Oncothyreon (ONTY) and Vical (VICL - Get Report). And let's not forget that obesity drug stocks Arena Pharma (ARNA - Get Report) and Vivus (VVUS) should be volatile again in 2012.

Let's talk about these stocks today, or any other biotech investing subjects that pique your interest. Please join me live.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BPAX $55.05 -1.24%
ARNA $1.72 0.00%
ALXA $0.64 0.00%
ONTY $1.30 0.00%
VICL $0.40 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs